1. Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells
- Author
-
Charlotte Taylor, Sandra Herrero-Gonzalez, Yiyan Zheng, David Mannion, Mohammad KaramiNejadRanjbar, Ahmed Ashour Ahmed, Karin Hellner, Robert C. Bast, Geoffrey Bartholomeusz, and Fabrizio Miranda
- Subjects
0301 basic medicine ,Programmed cell death ,Cell cycle checkpoint ,Paclitaxel ,Phosphofructokinase-2 ,Blotting, Western ,Fluorescent Antibody Technique ,Antineoplastic Agents ,Polymerase Chain Reaction ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,PFKFB3 ,PFKFB4 ,Cell Line, Tumor ,Humans ,Medicine ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Ovarian Neoplasms ,Cell Death ,business.industry ,Cancer ,mitotic arrest ,Cell Cycle Checkpoints ,Flow Cytometry ,medicine.disease ,Molecular medicine ,ovarian cancer ,030104 developmental biology ,Oncology ,chemistry ,Gene Knockdown Techniques ,030220 oncology & carcinogenesis ,Immunology ,Mutagenesis, Site-Directed ,Cancer research ,Female ,business ,Ovarian cancer ,Proto-Oncogene Proteins c-akt ,Research Paper - Abstract
// Charlotte Taylor 1, 2 , David Mannion 1, 2 , Fabrizio Miranda 1, 2 , Mohammad Karaminejadranjbar 1, 2 , Sandra Herrero-Gonzalez 1, 2 , Karin Hellner 1, 2 , Yiyan Zheng 1, 2 , Geoffrey Bartholomeusz 3 , Robert C. Bast Jr 3 , Ahmed Ashour Ahmed 1, 2 1 Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford, OX3 9DS, UK 2 Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Women’s Centre, John Radcliffe Hospital, Oxford, OX3 9DU, UK 3 Department of Experimental Therapeutics, M.D. Anderson Cancer Center, University of Texas, Houston, TX 77030, USA Correspondence to: Ahmed Ashour Ahmed, email: ahmed.ahmed@obs-gyn.ox.ac.uk Keywords: ovarian cancer, paclitaxel, mitotic arrest, PFKFB4, PFKFB3 Received: July 26, 2016 Accepted: December 15, 2016 Published: January 31, 2017 ABSTRACT Taxanes represent some of the most commonly used chemotherapeutic agents for ovarian cancer treatment. However, they are only effective in approximately 40% of patients. Novel therapeutic strategies are required to potentiate their effect and improve patient outcome. A hallmark of many cancers is the constitutive activation of the PI3K/AKT pathway, which drives cell survival and metabolism. We discovered a striking decrease in AKT activity coupled with a significant reduction in glucose 6-phosphate and ATP levels during mitotic arrest in the majority of ovarian cancer cell lines tested, indicating a potential metabolic vulnerability. A high-content siRNA screen to detect novel metabolic targets in mitotically arrested ovarian cancer cells identified the glycolytic enzyme PFKFB4. PFKFB4 depletion increased caspase 3/7 activity, and levels of reactive oxygen species only in mitotically arrested cells, and significantly enhanced mitotic cell death after paclitaxel treatment. Depletion of PFKFB3 demonstrated a similar phenotype. The observation that some ovarian cancer cells lose AKT activity during mitotic arrest and become vulnerable to metabolic targeting is a new concept in cancer therapy. Thus, combining mitotic-targeted therapies with glycolytic inhibitors may act to potentiate the effects of antimitotics in ovarian cancer through mitosis-specific cell death.
- Published
- 2017
- Full Text
- View/download PDF